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Neuroendocrine gut and pancreatic tumors are known to contain and secret dif-
ferent peptide hormones and amines. During the last two decades, many
radioimmunoassays andElizas have beendeveloped to analyze these substances
in blood and urine, which has enabled clinicians to improve the diagnosis and
monitoring of patients with various neuroendocrine tumors. Due to cost con-
straints in medical care, it is important to try to define the most useful bio-
chemical markers from the clinical point of view.
The glycoprotein chromogranin A has been shown to be a useful marker for
diagnosing various neuroendocrine tumors, both by histopathology and circu-
lating tumor markers. In patients with demonstrable endocrine tumors, about 90
percent ofthe patients present high circulating levels ofchromograninA. A hun-
dred-fold increase ofplasma chromogranin is seen in patients with midgut car-
cinoid tumors and liver metastases. Theplasmalevels ofchromogranin A reflect
the tumor mass and can be used for monitoring the patient during treatment and
follow-up, although the day-to-day variation might be 30-40 percent. High cir-
culating levels ofthe chromogranin A might be an indicator ofbad prognosis in
patients with malignant carcinoid tumors.
Besides analyzing plasma chromogranin A, specific analyses such as urinary 5-
HIAA in midgut carcinoid patients, serum gastrin in patients with Zollinger-
Ellison syndrome and insulin/proinsulin in patients with hypoglycemia should
be performed. In patients with small tumor masses or intermittent symptoms,
provocative tests such as a meal stimulation test, secretin test or pentagastrin
stimulation of tachykinin release can supplement the basal measurements of
peptides and amines. To fully evaluate the growth potential in neuroendocrine
tumors, traditional biochemical markers should be supplemented with indica-
tors ofgrowth proliferation (Ki-67, PCNA) and immunohistochemical staining
for the adhesion molecule CD44 and the PDGF-a receptor. Finally, analysis of
somatostatin receptor subtypes and induction of the enzymes 2-5A syntethase
and PKR are ofclinical value.
INTRODUCTION
Neuroendocrine gut and pancreatic tumors are known to contain and secrete different
peptide hormones and amines. During the lasttwo decades, many radioimmunoassays and
Elizas have been developed for analyzing peptide hormones and amines in the blood and
urine. Such assays have enabled clinicians to improve the diagnosis and monitoring of
patients with various neuroendocrine tumors.
There are several well-known clinical syndromes related to specific hormone pro-
duction in patients with endocrine pancreatic tumors. The most frequent type of
endocrine pancreatic tumor, which also can be confined in the duodenum and rarely out-
side the gut, is the gastrinoma, producing high amounts ofgastrin causing the Zollinger-
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Ellison syndrome. The second most common clinical syndrome is the hypoglycemic or
insulinoma syndrome, due to an endocrine pancreatic tumor producing insulin orproin-
sulin. More rare clinical syndromes are the so-called glucagonoma syndrome and WDHA
syndrome. In the former, a glucagon-producing tumor is found in the pancreas with pro-
duction of glucagon or proglucagon with a typical skin rash, the so-called necrolytic
migratory erythema, but also anemia, weight loss and diarrhea. The WDHA syndrome, or
VIP-oma syndrome, is causedby a tumorproducing VIP or PHI, which might be located
either in the pancreas, in the lung or in the adrenals. Somatostatin-producing tumors are
found in a small number ofpatients with endocrine pancreatic tumors or duodenal carci-
noids. These patients might present gall stones, diarrhea and diabetic glucose tolerance.
Most ofthesepatients showvery mild clinical symptoms and are often considered to have
a"nonfunctioning" islet cell tumor. It should be noted that most malignant tumors pro-
duce concomitantly several peptide hormones and amines and might shift from one clin-
ical syndrome to anotherduring the course ofthe disease. About one-third of the patients
with endocrine pancreatic tumors do not present any clinical hormone related syndrome
and are so called "non-functioning" islet cell tumors. These tumors are, from a biochem-
ical point ofview, functioning because they are secreting various hormones such as pan-
creatic polypeptide, chromogranin A and B, HCG-alpha and beta subunits, neurotensin,
PYY, and so forth. Sometimesthey are alsoproducingbiologically inactive forms ofother
peptide hormones [1].
The most commontype ofneuroendocrine GEP tumor is the midgut carcinoid, which
presents the carcinoidsyndrome when liver metastases arepresent. This syndrome is relat-
ed to secretion ofserotonin, tachykinins such as neurokinin A and substance P, as well as
bradykinins and prostaglandins. Foregut carcinoids are confined to the lung or gastric or
duodenal mucosa andmightproduce a lot ofdifferentpeptide hormones and amines. Lung
carcinoids might secreteACTH, GHRH, CRF,ADH, gastrin, VIP, pancreatic polypeptide,
HCG-alpha and beta subunits. Thepatientsmightpresent various clinical syndromes relat-
ed to this hormone production such as Cushing's syndrome, acromegaly and even the
Zollinger-Ellison syndrome. Gastric neuroendocrine tumors, for example the ECL-oma,
may produce histamin, serotonin as well as chromogranin A. Duodenal carcinoids might
producegastrin as well as somatostatin and alsochromogranin A. Hindgut carcinoids with
the primary tumors located in the distal part of colon or rectum are mostly non-function-
ing from the clinicalpoint ofview, buttheymayproduce peptidehormones such as PYY,
PP, HCG-alpha and beta as well as chromogranin A [2].
For the biochemical work-up in patients with neuroendocrine GEP tumors, all these
peptides mentioned above can be analyzed both by histopathology as well as by radioim-
munoassays and Elizas for detection in the plasma or serum using antibodies against the
different hormones and amines. Today, however, due to increased costs of medical care, it
is important to attempt a cost-benefit analysis when trying for the ultimate biochemical
diagnosis of these tumors. When the patients suffer small tumors or present intermittent
symptoms, provocative tests might supplement basal measurements of peptides and
amines. Today it is also of interest to combined the biochemical characterization of neu-
roendocrine tumors with markers for cellproliferation, cell adhesion, growth factor/recep-
tor expression, content of somatostatin receptor subtypes and also induction of specific
enzymes induced by interferon such as P 68 kinase (PKR) and 2-5A synthetase.
This overview will discuss a general tumor marker for neuroendocrine tumor, chro-
mograninA and also morespecificallybiochemicaldiagnosis ofpatients with midgut car-
cinoids, the Zollinger-Ellison syndrome andhypoglycemia. Useful stimulatory tests will
be presented, and in the end, markers oftumor biology.
502Oberg: Biochemical diagnosis ofneuroendocrine GEP tumor
CHROMOGRANIN A
Chromogranins or secretogranins constitute a family of water-soluble glycoproteins,
widely distributed in the secretory granules ofthe neuroendocrine tissues. The physiolog-
ical role of the molecules is unclear, but a number of possible biological functions have
been postulated including regulation of secretory granule function and serving as a pre-
cursor molecule for biologically active peptides [3].
Chromogranins can serve as cytochemical markers forneurendocrine tissues and as a
diagnostic tool for neuroendocrine tumors. Because of their water-soluble properties,
chromogranins are secreted together with peptide hormones and can be detected in the
blood by radioimmunoassay techniques. Accordingly, chromogranins can serve as circu-
lating tumor markers for neuroendocrine tumors ofdifferent origin [4, 5].
ChromograninA is a48 kd glycoprotein, which is stored in the large dense core vesi-
cles containing protein and peptide hormones. The gene on chromosome 14 encode for a
single amino acid chain with an terminal signal peptide that directs the protein into the
trans-Golgi regulated pathway [6]. Chromogranin A contains several di-basic amino acid
positions that serve as potential cleavage sites for production ofbiological active peptides
[7]. Identified peptides with established biological functions derived from chromogranin
A are pancreastatin (CgA 249-301), P-granin (CgA 1-114), chromostatin (CgA 124-343)
and vasostatin CgA 1-77 [7] (Figure 1). Other members of the chromogranin or secre-
togranin family are chromogranin B or secretogranin I and chromogranin C or secre-
togranin II. These two members share similarproperties but are stored in different tissues.
Chromogranin A as well as chromogranin B are originally isolated from chromaffin cells
in the bovine adrenal medulla, whereas chromogranin C was isolated from the anterior
pituitary. Chromogranin A and B are present in the human adrenal medulla in about equal
amounts, but chromogranin C is mainly found in the pituitary [8, 9]. The main source of
circulating chromogranin A is the adrenal medulla, but other neuroendocrine tissues con-
tribute [10].
CHROMOGRANINS AS TUMOR MARKER
In a recent study, we developed specific antibodies against chromogranin A, B and C
as well as pancreastatin [11]. The antibodies were used for immunohistochemical stain-
ing ofnormal and neoplastic neuroendocrine tissue and development ofreliable radioim-
munoassays for chromogranin A, B and C as well as pancreastatin. In 44 patients with
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Figure 1. The chromogranin A molecule. Arrows indicate di-basic cleavage sites CST, chromo-
statin; PANCST, pancreastatin; PARAST, parastatin.
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carcinoid tumors, 17 patients with sporadic endocrine pancreatic tumors and 11 patients
with endocrine pancreatic tumors and the MEN I syndrome, plasma measurements
revealed elevated chromogranin A levels in 99 percent, chromogranin B in 88 percent,
chromogranin C injust six percent andpancreastatin in 46percent ofthepatients (Figure.
2). Urinary measurements ofthe same peptides revealed lower numbers ofpatients with
elevated levels in 39 percent, 15 percent, 14 percent and 33 percent, respectively. Gel per-
metion chromatography ofplasma and urine from nine patients showed that the circulat-
ing chromogranin A has a higher molecular weight than chromogranin A excreted to the
urine [12].
Chromogranin A is increased in about 90 percent of patients with various neuroen-
docrine tumors, however, somewhat lower number ofpatients with increased levels have
been found in insulinomas. In those patients, chromogranin B might be a more useful
marker. Although pancreastatin is a fragment of chromogranin A, it is a less sensitive
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Figure 2. Plasma levels ofchromogranin A, B, C and pancreastatin in patients with carcinoids
(Car), endocrine pancreatid tumors (EPT) ormultiple endocrine neoplasia type I (MEN 1). N,
normal individuals.
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marker than chromogranin A for neuroendocrine tumors [12]. One reason might be that
many tumors are lacking necessary enzymes that can cleave off the peptide at di-basic
cleavage sites. Therefore, a specific pancreastatin antibody does notrecognize such afrag-
ment. In patients with Multiple Endocrine Neoplasia type 1 (MEN I), measurements of
chromogranin A is a less sensitive marker than in sporadic cases of endocrine pancreatic
tumors or patients with carcinoid tumors. The sensitivity was 76 percent in a study we
recently performed (to be published), and, therefore, this analysis should be supplement-
ed with other diagnostic tests, such as a meal stimulation with a sensitivity of 85 percent.
Falsely elevated levels of chromogranin A can be found in patients with impaired renal
function, essential hypertonia and some patients with inflammatory bowel disease. In gen-
eral, the levels of chromogranin A are significantly lower in these patients, usually less
than 10 nmol/l. However, this might generate problems in the early diagnosis ofendocrine
pancreatic tumors since patients with only primary tumors can provide chromogranin A
levels between 5 and 10 nmol/l. Patients with metastatic disease usually present 10-fold
higher levels, and, in particular, patients with classical carcinoid tumors present 100-fold
higher levels when liver metastases have developed. There is a good correlation between
chromogranin A levels and the tumor size in neuroendocrine tumors, which has particu-
larly been shown for classical midgut carcinoids. In a multivariate analysis, we could
demonstrate that high levels of chromogranin A correlated to a significantly worse prog-
nosis than patients with lower levels of chromogranins A (to be published). This might
indicate that chromogranin A or fragments of it might have growth promoting effects.
Plasma chromogranin A levels are suitable for monitoring patients during treatment.
However, day-to-day variation in patients with endocrine tumors is median 38 percent,
which should be taken into consideration.
SPECIFIC BIOCHEMICAL MARKERS
In patients with classical midgut carcinoid tumors, chromogranin A in plasma
together with urinary 5-HIAA are the corner stones forbiochemical diagnosis. In a study
of 301 carcinoid patients (Table 1), urinary 5-HIAA was increased in 76 percent of the
patients, chromogranin A in 87 percent and plasma neuropeptide K in 46 percent. With
respect to foregut carcinoids, urinary 5-HIAA was only increased in 31 percent, plasma
Table 1. Timor markers in 301 carcinoid patients.
Increased Median Refs.
(percent) level range
Midgut
U-5HIAA 76 285 ,umoV24 hr <80 pmol/24 hr
p-Chromogranin A 87 2.300 pg/l <350 pg/l
p-Neuropeptide K 46 23 pmoll <16pmolIl
Foregut
U-5HIAA 31 85 ,umol/24 hr
p-Chromogranin A 79 847 pg/l
p-Neuropeptide K 9 20pmoIl
Hindgut
U-5HIAA 0 33 pmol/24 hr
p-Chromogranin A 100 727 pg/l
p-Neuropeptide K 0 7.8 pmolIl
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chromogranin A in 79 percent and neuropeptide K in nine percent. In patients with
hindgut tumors, only chromogranin A was increased among these three markers, and it
was increased in 100 percent of the patients. In patients with the Zollinger-Ellison syn-
drome, measurements ofbasal (BAO) and maximal acid output (MAO) is mandatory, and
levels of BAO above 15 mekv/hour raises a suspicion of a Zollinger-Ellison syndrome.
This test is then supplemented by measurement of serum gastrin and chromogranin A. In
some patients, analyses of progastrin might be of value since some patient's tumors are
not able to process progastrin to amidated forms ofgastrin [13]. In patients with insulin-
producing tumors, measurement ofblood glucose together with serum insulin and proin-
sulin forms the basic biochemical diagnosis. Non-functioning neuroendocrine tumors are
often diagnosed in the late stage of the disease, and the most useful biochemical mark-
ers are chromogranin A, pancreatic polypeptide and HCG-alpha and beta subunits. Some
patients can also be diagnosed by measurements of C-A 19-9 and C-A 50.
STIMULATORY TEST
There are some useful stimulatory tests for the diagnosis of neuroendocrine tumors.
One is a meal stimulatory test, with a standardized meal containing totally 563 kcal (66 g
carbohydrates, 18 g proteins and 22 g lipids) [14]. Measurements ofpancreatic polypep-
tide and gastrin are performed during the meal and have been particularly useful in
patients with MEN I with endocrine pancreatic tumors. The biochemical diagnosis of an
endocrine pancreatic tumor can be obtained four to five years before radiological detec-
tion of the tumor. Another important stimulatory test is the secretin test for patients with
suspected gastrinomas, where 2 CU of secretin is infused intravenously and gastrin sam-
pling occurs during 20 minutes after the infusion. Serum gastrin increments ofabout 200
pg/ml or 50 percent increase of basal gives a sensitivity of 75-85 percent [15]. Calcium
infusion test with measurementofgastrin can be used in selected cases butwith lower sen-
sitivities (40-70 percent) [15, 16]. Pentagastrin stimulation of tachykinin release in
patients with carcinoid tumors might be of value for early detection of classical midgut
carcinoids. Pentagastrin 0.6 gg/kg is injected with measurements of tachykinin for 20
minutes. A positive test shows a peak within five minutes after injection [17].
MARKERS OF TUMOR BIOLOGY
Besides a characterization of the hormone production in different neuroendocrine
tumors, it is ofvalue to try to evaluate the growthpotential ofthe tumors. This can be done
by staining tissue sections for proliferation markers such as Ki67 or PCNA [18]. Other
informative markers might be the adhesion molecule CD44 where expression of higher
molecular forms of CD44 is related to worse prognoses in many malignancies [19].
Another marker ofbad prognosis is the expression of PDGF-a receptor, which has been
shown both for ovarian tumor as well as carcinoids [20]. A complete work-up in these
patients should also include analyses of subtypes of somatostatin receptors and induction
of 2-SA syntethase as well as PKR. The last two being enzymes that are induced by x-
interferon and can be used as prognostic markers [21].
In conclusion, the basis for biochemical diagnoses in neuroendocrine tumors is mea-
surements ofchromograninA, which can be used as ageneral screening markerbut should
be supplemented in the various syndromes with the more specific analyses such as urinary
5-HIAA in patients with carcinoid tumors, gastrin in Zollinger-Ellison patients and
insulin/pro-insulin in hypoglycemic patients. For monitoring patients during treatment,
chromogranin A is a good marker to follow, although the day-to-day variation might be as
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high as 38 percent. Plasma levels ofchromogranin A mightbe ofprognostic value for car-
cinoid patients. Assessments ofparameters for tumor growth potential and tumor biology
should be included in the future to be able to improve the therapeutic outcome.
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